Zenara Pharma receives DCGI approval to manufacture and sell Favipiravir tablets - (India Infoline via NewsPoints Desk)

  • Zenara Pharma, a subsidiary of Biophore India Pharmaceuticals, received approval from the Drugs Controller General of India (DCGI) to manufacture and sell favipiravir for patients with mild-to-moderate symptoms of COVID-19, reported India Infoline.

  • The drug, which will be sold under the brand name Favizen, is being manufactured at Zenara's FDA-approved facility in Hyderabad.

  • Managing director Jagadeesh Babu Rangisetty remarked "I am proud to say that we have our own in-house API (active pharmaceutical ingredients) and are not dependent on any imports for the production."

  • "We believe that this will ensure stability and rapid production and availability of this treatment for the Indian market," the executive added.

To read more NewsPoints articles, click here.